Novel treatment for triple-negative breast and ovarian cancer: Endogenous opioid suppression of women's cancers

Expert Review of Anticancer Therapy

Volumn 14, Issue 3, 2014, Pages 247-250

  McLaughlin, Patricia J ^a   Zagon, Ian S ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

cell proliferation; enkephalins; opioid growth factor; ovarian cancer; triple negative breast cancer

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; METENKEPHALIN; OPIATE; OPIATE RECEPTOR; OPIOID GROWTH FACTOR; OPIOID GROWTH FACTOR RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; CELL DIFFERENTIATION; CELL DIVISION; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN MDA MB 231; DNA MODIFICATION; DNA SYNTHESIS INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; TRIPLE NEGATIVE BREAST CANCER; WOMEN'S HEALTH;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; HUMANS; MICE; MICE, NUDE; OPIOID PEPTIDES; OVARIAN NEOPLASMS; RECEPTORS, OPIOID;

EID: 84896695231     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2014.867234     Document Type: Review

References (20)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 63, 11-30 (2013)
2. Gluz O, Liedtke C, Cottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer - current status and future directions. Ann. Oncol. 20, 1913-1927 (2009)
3. Bankhead C. Triple-negative breast cancer has highest hospitalizations, mortality rates. Value-Based Cancer Care (2011)
4. Zagon IS, Verderame MF, McLaughlin PJ. The biology of the opioid growth factor receptor (OGFr) Brain Res. Rev. 38(3), 351-376 (2002)
5. McLaughlin PJ, Zagon IS. The opioid growth factor - opioid growth factor receptor axis: homeostatic regulation of cell proliferation and its implications for health and disease. Biochem. Pharmacol. 84(6), 746-755 (2012)
6. Zagon IS, Donahue R, McLaughlin PJ. Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer. Exp. Biol. Med. 38(5), 579-587 (2013)
7. Zagon IS, Porterfield NK, McLaughlin PJ. Opioid growth factor - opioid growth factor axis inhibits proliferation of triple negative breast cancer. Exp. Biol. Med. 238, 589-599 (2013)
8. Donahue RN, McLaughlin PJ, Zagon IS. Low-dose naltrexone suppresses ovarian cancer and exhibit enhanced inhibition in combination with cisplatin. Exp. Biol. Med. 236, 883-895 (2011)
9. Donahue RN, McLaughlin PJ, Zagon IS. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice. Gynecol. Oncol. 122, 382-388 (2011)
10. Zagon IS, Donahue RN, McLaughlin PJ. Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers. Am. J. Physiol. Regul. Integr. Comp. Physiol. 297(4), R1154-R1161 (2009)
11. Brito DA, Yang Z, Rieder CL. Microtubules do not promote mitotic slippage when the spindle assembly checkpoint cannot be satisfied. J. Cell Biol. 82(4), 623-629 (2008)
12. Ozcelik B, Turkyilmaz C, Ozgun MT et al. Prevention of paclitaxel and cisplatin induced ovarian damage in rats by a gonadotropin-releasing hormone agonist. Fertil. Steril. 93 (5), 1609-1614 (2010)
13. Zagon IS, Jaglowski JR, Verderame MF, Leure-duPree AE, Smith JP, McLaughlin PJ. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma. Cancer Chemother. Pharmacol. 56, 510-520 (2005)
14. Jaglowski JR, Zagon IS, Stack BC Jr et al. Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck. Cancer Chemother. Pharmacol. 56, 97-104 (2005)
15. Donahue RN, McLaughlin PJ, Zagon IS. Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 296, R1716-R1725 (2009)
16. Fanning J, Hossler CA, Kesterson JP, Donahue RN, McLaughlin PJ, Zagon IS. Expression of the opioid growth factor - opioid growth factor receptor axis in human ovarian cancer. Gynec. Oncol. 124, 319-324 (2012)
17. Donahue RN, McLaughlin PJ, Zagon IS. Overexpression of the opioid growth factor receptor (OGFr) in human ovarian cancer cells downregulates cell proliferation in vitro and inhibits tumorigenesis in mice. J. Cancer Ther. 2, 579-594 (2011)
18. Donahue RN, Zagon IS, McLaughlin PJ. The opioid growth factor inhibits established ovarian cancer in nude mice and can be combined with taxol or cisplatin to enhance growth inhibition. J. Cancer Ther. 2, 110-124 (2011)
19. Smith JP, Ahmad M, Conter R et al. Treatment of advanced pancreatic cancer with opioid growth factor: Phase I. Anticancer Drugs 15(3), 203-209 (2004)
20. Smith JP, Bingaman SI, Mauger DT, Harvey HH, Demers LM, Zagon IS. Opioid growth factor improves clinical benefit and survival in patients with advanced pancreatic cancer. Open Access J. Clin. Trials 2010(2), 37-48 (2010)